Accessibility Menu
Aspire Biopharma logo

Aspire Biopharma

(NASDAQ) ASBP

Current Price$6.23
Market Cap$8.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-100%
5 YearN/A
1 Year-99%
1 Month-2%
Aspire Biopharma last closing stock price
MetricPriceDate
Last closeUSD 6.242026-07-17
Aspire Biopharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.83%USD 6.012026-07-10
1 month-1.89%USD 6.362026-06-17
3 month-22.88%USD 8.092026-04-17
Year to date-96.06%USD 158.282025-12-31
1 year-98.54%USD 427.202025-07-17
3 year-99.95%USD 12,679.802023-07-18
Since inception-99.95%USD 11,988.012022-04-11

Aspire Biopharma Financials at a Glance

Market Cap

$8.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$34.56K

Net Income (TTM)

-$11.76M

EPS (TTM)

-$153.56

P/E Ratio

-0.04

Dividend

$0.00

Beta (Volatility)

0.69 (Low)

Price

$6.23

Volume

142

Open

$6.14

Previous Close

$6.23

Daily Range

$6.11 - $6.23

52-Week Range

$3.31 - $1,050.36

Estimated Earnings Date

May 13, 2026

ASBP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aspire Biopharma

Aspire Biopharma develops fast-acting medicines and supplements for quick relief. Its products help people needing rapid pain, sleep, or energy solutions. The company focuses on new ways to deliver familiar drugs for easier use.

What’s in the Medicine Cabinet? (Products and Services)

  • Sublingual pharmaceuticals: High-dose aspirin and other drugs absorbed under the tongue for rapid effect (0% of revenue).
  • Nutraceuticals and supplements: Melatonin and vitamins D, E, K for sleep and wellness (0% of revenue).
  • Caffeine supplements: Fast-acting caffeine powders for alertness, sold via Buzz Bomb Caffeine Co. (0% of revenue).
  • Pipeline products: Testosterone, semaglutide, anti-nausea, and seizure medications in development (0% of revenue).

Growth Spurts and Growing Pains (Growth and Expansion)

  • Completed business combination with PowerUp Acquisition Corp. in February 2025, leading to public listing.
  • Signed manufacturing deals with Glatt (aspirin) and Desert Stream, Inc. (caffeine) in 2025.
  • Launched Buzz Bomb Caffeine Co. for caffeine products in 2025.
  • Filed multiple patent applications for sublingual drug delivery technology in 2024 and 2025.
  • Completed clinical trial for high-dose sublingual aspirin in July 2025; NDA submission planned.

Why Aspire Stands Out (Special Features)

Aspire uses sublingual delivery, letting drugs absorb quickly under the tongue. This method may reduce stomach side effects and speed up relief. The company holds pending patents and has no direct competitors for sublingual aspirin in the FDA Orange Book.

Five Things You Need to Know (Financial Highlights)

  • Revenue was $0 in Q2 2025, unchanged from Q2 2024 (0% change).
  • Operating expenses rose to $799,890 in Q2 2025, up 725.3% from Q2 2024.
  • Net loss reached $1.98 million in Q2 2025, up from $96,923 in Q2 2024.
  • Cash was $206,233 as of June 30, 2025, with a $9.6 million working capital deficit.

Bottom Line

Aspire Biopharma is an early-stage biotech focused on new drug delivery methods. The company faces high costs and no revenue as it develops its first products.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

2

CEO

Kraig T. Higginson

Website

www.aspirebiolabs.com

Headquarters

Estero, FL 33928, US

ASBP Financials

Key Financial Metrics (TTM)

Gross Margin

16.30%

Operating Margin

-15745.85%

Net Income Margin

-34039.68%

Return on Equity

199.43%

Return on Capital

N/A

Return on Assets

-165.27%

Earnings Yield

-25.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$8.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.30M

Volume

142

Avg. Volume

802.71K

Financials (TTM)

Gross Profit

$5.63K

Operating Income

-$5.44M

EBITDA

$4.28M

Operating Cash Flow

-$6.21M

Capital Expenditure

$0.00

Free Cash Flow

-$6.21M

Cash & ST Invst.

$5.86M

Total Debt

$1.50M

Aspire Biopharma Performance Analysis

Aspire Biopharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 6,202N/A
Aspire Biopharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31119.5%
Q12026-03-31565.4%
Aspire Biopharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 111.54N/A
20232023-12-31USD 279.31150.4%
20242024-12-31USD -56.96N/A
20252025-12-31USD -491.27762.4%
Aspire Biopharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3090.4%
Q32025-09-307.5%
Q42025-12-31-111.4%
Q12026-03-3131.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$28.35K

N/A

Gross Profit

$5.75K

N/A

Gross Margin

20.28%

N/A

Market Cap

$8.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.04M

N/A

Employees

2

N/A

Net Income

-$3.22M

+79.8%

EBITDA

-$62.28K

+99.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$5.86M

+335.0%

Total Debt

$1.50M

-77.8%

Accounts Receivable

$0.00

N/A

Inventory

$369.97K

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$1.50M

-77.8%

Return on Assets

-1.65%

N/A

Return on Invested Capital

-1.37%

N/A

Free Cash Flow

-$3.04M

-73.5%

Operating Cash Flow

-$3.04M

-73.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CAUDCollective Audience, Inc.
$0.00+0.00%
FIACFocus Impact Acquisition Corp.
$8.88-10.48%
GAMCGolden Arrow Merger Corp.
$9.00-22.41%
BOCNBlue Ocean Acquisition Corp.
$10.72N/A

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
AALAmerican Airlines Group
$14.98-0.04%
NOKNokia
$10.12-0.03%
PATHUiPath
$12.15+0.01%

Questions About ASBP

What is the current price of Aspire Biopharma?

Aspire Biopharma is trading at $6.23 per share.

What is the 52-week range for Aspire Biopharma?

Over the past 52 weeks, Aspire Biopharma has traded between $3.31 and $1,050.36.

How much debt does Aspire Biopharma have?

As of the most recent reporting period, Aspire Biopharma reported total debt of $1.50M.

How much cash does Aspire Biopharma have on hand?

Aspire Biopharma reported $5.86M in cash and cash equivalents in its most recent financial results.

What is Aspire Biopharma’s dividend yield?

Aspire Biopharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services